US Congress House Bill 3199 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Introduced on June 11 2019 - 25% progression, died in committee
Action: 2019-06-28 - Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Pending: House Subcommittee on Courts, Intellectual Property, And The Internet Committee
Text: Latest bill text (Introduced) [PDF]

Addresses double patenting with respect to drug-related patents. Specifically, the bill requires an owner of drug-related patents, if the owner lists more than one patent as covering a particular drug, to prove in certain proceedings that each patent covers a distinct invention. If the patent owner fails to do so, then the owner shall have disclaimed patent protection from all the listed patents after the first patent expires. This requirement shall apply to various proceedings challenging the validity of drug-related patents, as well as to infringement lawsuits filed by the patent owner against companies seeking Food and Drug Administration approval for generic or biosimilar versions of patented drugs. The bill also directs the U.S. Patent and Trademark Office (USPTO) to review its examination procedures to prevent granting multiple patents for the same drug or biological product, unless the patents cover distinct inventions. The USPTO shall report to Congress its findings and recommendations from the review.

Term Act of 2019 Terminating the Extension of Rights Misappropriated Act of 2019

Rep. Hakeem Jeffries [D-NY]	Rep. Doug Collins [R-GA]	Rep. Debbie Mucarsel-Powell [D-FL]	Rep. Ben Cline [R-VA]
Rep. Chip Roy [R-TX]	Rep. Bobby Rush [D-IL]

Date	Chamber	Action
2019-06-28	House	Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
2019-06-11	House	Referred to the House Committee on the Judiciary.
2019-06-11	House	Introduced in House

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/house-bill/3199/all-info
Text	https://www.congress.gov/116/bills/hr3199/BILLS-116hr3199ih.pdf